Clinical biotech research trials are an important part of the process used to evaluate new medicines, biological products, diagnostic technologies, and other medical approaches. Biotechnology companies, universities, hospitals, and research organizations conduct studies to investigate how potential treatments work, how the body responds to them, and whether their benefits outweigh potential risks.
Clinical trials are structured research studies involving human participants.
In biotechnology, trials can evaluate products such as:
The goal depends on the study. Early research may focus primarily on safety and how the body processes an investigational product, while later-stage studies can evaluate effectiveness and compare outcomes with existing treatments or control groups.
Clinical trials are conducted according to predefined protocols that describe how the study will be carried out.
Before an investigational biotechnology product reaches human clinical testing, researchers generally conduct laboratory and preclinical research.
Preclinical studies can involve laboratory experiments and animal studies, depending on the product and regulatory requirements.
Researchers examine questions such as:
The evidence generated during these stages helps inform applications to regulatory authorities and study designs for clinical research.
Phase 1 is generally the first stage of testing an investigational medical product in humans.
These studies commonly focus on safety, tolerability, dosage, and pharmacokinetics or pharmacodynamics.
A Phase 1 study may involve a relatively small number of participants.
Researchers can monitor:
Some biotechnology trials involve patients rather than healthy volunteers from the beginning, particularly when an investigational product is intended for serious diseases or when healthy participants would not be appropriate.
Phase 2 studies generally involve participants who have the disease or condition being investigated.
Researchers continue evaluating safety while gathering information about whether the treatment appears to have a therapeutic effect.
Phase 2 studies can also help researchers determine appropriate doses and treatment schedules for later studies.
Depending on the research program, Phase 2 trials can involve dozens or hundreds of participants.
Results from Phase 2 research may influence the design of larger Phase 3 studies.
Phase 3 trials are generally larger studies designed to provide additional evidence about effectiveness and safety.
Participants may be assigned to different treatment groups, including an investigational treatment, an existing treatment, or a placebo when appropriate.
Researchers may evaluate outcomes such as:
Phase 3 trials can involve hundreds or thousands of participants, depending on the disease and research question.
Data from successful late-stage trials can contribute to regulatory submissions seeking approval for broader use.
Research does not necessarily end after a product receives regulatory approval.
Post-marketing studies can provide additional information about safety, effectiveness, long-term outcomes, and use in broader populations.
These studies may identify uncommon adverse events that are difficult to detect in earlier trials because the earlier studies involved fewer participants.
Additional research can also examine how a treatment performs in routine clinical settings.
Randomization is commonly used in clinical research to reduce the influence of factors that could otherwise affect study results.
In a randomized trial, participants are assigned to study groups according to a predetermined process rather than simply choosing which treatment they receive.
Randomization can help researchers compare outcomes between groups more objectively.
The exact randomization approach varies according to the study design.
Some clinical trials use a placebo.
A placebo is designed to resemble the investigational treatment without containing the active therapeutic component being studied.
Placebo-controlled research can help investigators determine whether observed effects are associated with the investigational treatment rather than other factors.
However, placebo use is not appropriate for every clinical situation. Ethical considerations and available standard treatments influence whether a placebo-controlled design can be used.
Clinical studies can also use blinding.
In a single-blind study, participants may not know which treatment they receive.
In a double-blind study, participants and certain study personnel may not know treatment assignments during the relevant part of the trial.
Blinding can reduce the possibility that expectations influence how outcomes are measured or reported.
Some trials cannot be fully blinded because the treatments have obvious differences or require procedures that reveal the assignment.
Every clinical trial has eligibility criteria.
These criteria can include:
Eligibility requirements are designed to identify a population appropriate for answering the research question and to protect participant safety.
Meeting one or more criteria does not guarantee enrollment.
Clinical trial eligibility criteria commonly have two categories.
Inclusion criteria describe characteristics participants generally must have to enter a study.
Examples can include a particular diagnosis, age range, disease stage, or previous treatment history.
Exclusion criteria identify circumstances that may prevent participation.
Examples can include certain medical conditions, medications, laboratory abnormalities, or previous treatments.
The exact criteria differ between trials.
Participant safety monitoring is a central part of clinical research.
Depending on the study, monitoring can include:
The frequency of these assessments is defined in the study protocol.
Participants should report new symptoms or other concerns to the clinical research team according to the instructions provided by the study.
Before participating in a clinical trial, potential participants generally receive information about the study through an informed-consent process.
The information can include:
Informed consent is intended to help participants make an informed decision about whether to participate.
Signing a consent document does not mean that the participant gives up all rights or agrees to remain in the study regardless of circumstances.
Clinical trial participation is generally voluntary.
Participants can usually withdraw from a study according to the study's procedures.
The research team may also stop a participant's involvement if continuing would no longer be appropriate or if the study protocol requires discontinuation.
Participants should discuss withdrawal procedures with the research team because certain follow-up assessments may be important for safety.
Clinical research is subject to regulatory and ethical oversight.
In the United States, the Food and Drug Administration regulates many medical products and oversees aspects of clinical research involving investigational products.
Institutional Review Boards, commonly called IRBs, review many clinical studies involving human participants to evaluate ethical and safety considerations.
Researchers must also follow the applicable study protocol and regulatory requirements.
The exact regulatory framework can differ between countries.
ClinicalTrials.gov is a major U.S.-based public resource containing information about clinical studies.
Study records can include:
Not every study listed on a public registry is currently recruiting.
Recruitment status should therefore be checked before contacting a study team.
A clinical-trial search can begin with the condition or type of biotechnology intervention being studied.
Useful search criteria can include:
Search results should be reviewed carefully because similar studies can have substantially different eligibility requirements.
Before joining a clinical trial, potential participants may want to ask:
The answers should be provided by the study team and reviewed against the official consent materials.
Clinical research can provide access to an investigational treatment that is not yet broadly approved for routine use.
Participants may also contribute information that helps researchers understand a disease or evaluate a potential treatment.
However, participation does not guarantee that an investigational treatment will work.
A study may also reveal that a treatment is ineffective or causes unexpected problems.
Clinical trials can involve risks.
An investigational treatment may have side effects that are not yet fully understood.
Other considerations can include:
The study's informed-consent materials should explain known and reasonably foreseeable risks.
Some biotechnology trials use biomarkers to identify participants who may be more likely to respond to an investigational treatment.
Biomarkers can include genetic characteristics, proteins, molecular signatures, or other measurable biological features.
This approach is particularly relevant to precision medicine.
A trial may therefore require participants to undergo additional laboratory testing before eligibility can be determined.
Cell and gene therapies represent specialized areas of biotechnology research.
Cell therapy involves using cells as part of a therapeutic approach, while gene therapy seeks to modify or introduce genetic material for a therapeutic purpose.
These studies can involve specialized manufacturing, administration procedures, long-term monitoring, and complex eligibility requirements.
Because these technologies can have effects that persist for extended periods, follow-up requirements may be longer than those used in some conventional drug studies.
Biotechnology research also plays an important role in vaccine development and other biologic products.
Clinical trials can evaluate:
Different vaccine and biologic technologies can require different research designs.
The financial arrangements for clinical trials vary.
A study sponsor may cover certain research-related expenses, while routine medical care can be handled separately.
Potential costs can include:
Some studies provide participant compensation for time and travel.
The informed-consent documents and research team should explain which expenses are covered and whether compensation is provided.
Clinical trials can be sponsored by different organizations.
Sponsors can include:
A study can also involve several collaborating organizations.
The sponsor is responsible for supporting the research according to applicable regulatory and protocol requirements.
Once a clinical trial reaches completion, researchers analyze the collected data.
The results can contribute to:
A successful trial does not automatically mean that a product will receive regulatory approval.
Regulatory authorities independently evaluate the available evidence according to the applicable framework.
They are structured human research studies evaluating biotechnology-based medicines, biological products, diagnostics, or other interventions.
Clinical trials include safety monitoring and ethical oversight, but no research study is completely risk-free. The potential risks depend on the intervention and study procedures.
No. Each trial has specific inclusion and exclusion criteria designed around the research question and participant safety.
Financial arrangements vary. Some study-related expenses may be covered by the sponsor, while routine medical costs and other expenses can be handled differently.
Not necessarily. Some studies use control groups or placebos when scientifically and ethically appropriate.
ClinicalTrials.gov is one major registry for finding information about clinical studies, particularly those involving the United States.
Clinical biotech research trials are a key part of developing and evaluating new medical technologies.
Studies can progress through multiple phases, beginning with early safety research and potentially advancing to larger studies examining effectiveness and longer-term safety. Biotechnology trials can involve medicines, vaccines, cell therapies, gene therapies, diagnostics, and other biological technologies.
Eligibility, procedures, risks, costs, and participation requirements differ from one study to another. Public clinical-trial registries can provide basic information, but the official study team and informed-consent documents remain important sources for understanding a particular trial.